Aims: To compare the efficacy and safety of bismuth quadruple therapy with concomitant therapy in the empirical eradication of Helicobacter pylori (H. pylori) infection. Methods: Such databases as PubMed, Embase and the Cochrane Library and Chinese databases (China National Knowledge Infrastructure (CNKI), Wanfang Data and CBM), were searched for relevant randomized controlled trials up to February 2020. Studies were included if they assessed the efficacy and safety of bismuth quadruple therapy versus concomitant therapy in H. pylori eradication. Statistical analysis was performed with RevMan software 5.3. Results: Four studies with 616 patients were evaluated in this meta-analysis. The H. pylori eradication rate of bismuth quadruple therapy was similar to that of concomitant therapy (intention-to-treat analysis: pooled eradication rates, 85.5% vs 80.7%; odds ratio [OR], 1.42; 95%confidence interval (CI): [0.92–2.18]; P>0.05). The incidence of adverse events in bismuth quadruple therapy was lower than those in concomitant therapy (pooled incidence, 18.3% vs 25.9%; OR, 0.62, 95%CI: [0.41–0.92]; P<0.05). Conclusions: Bismuth quadruple therapy had the same efficacy to concomitant therapy in H. pylori eradication, and bismuth quadruple therapy was possibly better tolerated than concomitant therapy. Therefore, bismuth quadruple therapy and concomitant therapy should be equally recommended as empirical regimens in H. pylori eradication.
| Published in | Biomedical Sciences (Volume 8, Issue 4) |
| DOI | 10.11648/j.bs.20220804.11 |
| Page(s) | 113-118 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Helicobacter pylori, Bismuth Quadruple Therapy, Concomitant Therapy, Meta-Analysis
| [1] | Leja M, Grinberga-Derica I, Bilgilier C, Steininger C. Review: Epidemiology of Helicobacter pylori infection. Helicobacter. 2019. 24 Suppl 1: p. e12635. |
| [2] | Malfertheiner P, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017. 66 (1): p. 6-30. |
| [3] | Liu WZ, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 2018. 23 (2): p. e12475. |
| [4] | Sasaki M, et al. Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. Journal of clinical biochemistry and nutrition 2010. 47 (1): p. 53-8. |
| [5] | Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010. 59 (8): p. 1143-53. |
| [6] | Venerito M, et al. Bismuth-containing quadruple therapy vs. standard triple therapy for empiric primary treatment of helicobacter pylori infection: Systematic review and meta-analysis of efficacy, tolerability and role of antibiotic resistance. Helicobacter 2012. 17: p. 99. |
| [7] | Saad RJ, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. The American journal of gastroenterology 2006. 101 (3): p. 488-96. |
| [8] | Wang Y, et al. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis. European journal of clinical pharmacology 2018. 74 (1): p. 1-13. |
| [9] | Chen MJ, et al. Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection. The American journal of gastroenterology 2018.113 (10): p. 1444-57. |
| [10] | Yang X, et al. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Medicine 2019. 98 (7): p. e14396. |
| [11] | Lyu QJ, et al. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials. BioMed research international 2019. 2019: p. 9781212. |
| [12] | Higgins JP, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj 2011. 343: p. d5928. |
| [13] | Uygun A, et al. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori. Turkish journal of gastroenterology 2012. 23 (1): p. 8-13. |
| [14] | Jheng GH, et al. Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection. BioMed research international 2015. 2015: p. 163960. |
| [15] | Li M Cost-effectiveness analysis of concomitant therapy and bismuth quadruple therapy for Helicobacter pylori eradication [Thesis]. Xinjiang Medical University, 2017. |
| [16] | Kim SJ, et al. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial. World journal of gastroenterology 2019. 25 (46): p. 6790-98. |
| [17] | Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999. 319 (7211): p. 670. |
| [18] | Mansour-Ghanaei F, et al. Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of Helicobacter pylori: a randomized, double-blind clinical trial. EXCLI journal 2019. 18: p. 644-52. |
| [19] | Bae HJ, et al. Concomitant or Sequential Therapy as the First-line Therapy for Eradication of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis. The Korean journal of gastroenterology 2018. 71 (1): p. 31-37. |
| [20] | Macias-Garcia F, et al. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial. Helicobacter 2019. 24 (1): p. e12546. |
| [21] | Graham DY, et al. A report card to grade Helicobacter pylori therapy. Helicobacter 2007. 12 (4): p. 275-8. |
| [22] | Hooi JKY, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology, 2017. 153 (2): p. 420-429. |
APA Style
Qiu Ju Lyu, Qiang Hong Pu. (2022). Comparative Efficacy and Safety of Bismuth Quadruple and Concomitant Therapy for Empirical Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials. Biomedical Sciences, 8(4), 113-118. https://doi.org/10.11648/j.bs.20220804.11
ACS Style
Qiu Ju Lyu; Qiang Hong Pu. Comparative Efficacy and Safety of Bismuth Quadruple and Concomitant Therapy for Empirical Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials. Biomed. Sci. 2022, 8(4), 113-118. doi: 10.11648/j.bs.20220804.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.bs.20220804.11,
author = {Qiu Ju Lyu and Qiang Hong Pu},
title = {Comparative Efficacy and Safety of Bismuth Quadruple and Concomitant Therapy for Empirical Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials},
journal = {Biomedical Sciences},
volume = {8},
number = {4},
pages = {113-118},
doi = {10.11648/j.bs.20220804.11},
url = {https://doi.org/10.11648/j.bs.20220804.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bs.20220804.11},
abstract = {Aims: To compare the efficacy and safety of bismuth quadruple therapy with concomitant therapy in the empirical eradication of Helicobacter pylori (H. pylori) infection. Methods: Such databases as PubMed, Embase and the Cochrane Library and Chinese databases (China National Knowledge Infrastructure (CNKI), Wanfang Data and CBM), were searched for relevant randomized controlled trials up to February 2020. Studies were included if they assessed the efficacy and safety of bismuth quadruple therapy versus concomitant therapy in H. pylori eradication. Statistical analysis was performed with RevMan software 5.3. Results: Four studies with 616 patients were evaluated in this meta-analysis. The H. pylori eradication rate of bismuth quadruple therapy was similar to that of concomitant therapy (intention-to-treat analysis: pooled eradication rates, 85.5% vs 80.7%; odds ratio [OR], 1.42; 95%confidence interval (CI): [0.92–2.18]; P>0.05). The incidence of adverse events in bismuth quadruple therapy was lower than those in concomitant therapy (pooled incidence, 18.3% vs 25.9%; OR, 0.62, 95%CI: [0.41–0.92]; PConclusions: Bismuth quadruple therapy had the same efficacy to concomitant therapy in H. pylori eradication, and bismuth quadruple therapy was possibly better tolerated than concomitant therapy. Therefore, bismuth quadruple therapy and concomitant therapy should be equally recommended as empirical regimens in H. pylori eradication.},
year = {2022}
}
TY - JOUR T1 - Comparative Efficacy and Safety of Bismuth Quadruple and Concomitant Therapy for Empirical Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials AU - Qiu Ju Lyu AU - Qiang Hong Pu Y1 - 2022/10/11 PY - 2022 N1 - https://doi.org/10.11648/j.bs.20220804.11 DO - 10.11648/j.bs.20220804.11 T2 - Biomedical Sciences JF - Biomedical Sciences JO - Biomedical Sciences SP - 113 EP - 118 PB - Science Publishing Group SN - 2575-3932 UR - https://doi.org/10.11648/j.bs.20220804.11 AB - Aims: To compare the efficacy and safety of bismuth quadruple therapy with concomitant therapy in the empirical eradication of Helicobacter pylori (H. pylori) infection. Methods: Such databases as PubMed, Embase and the Cochrane Library and Chinese databases (China National Knowledge Infrastructure (CNKI), Wanfang Data and CBM), were searched for relevant randomized controlled trials up to February 2020. Studies were included if they assessed the efficacy and safety of bismuth quadruple therapy versus concomitant therapy in H. pylori eradication. Statistical analysis was performed with RevMan software 5.3. Results: Four studies with 616 patients were evaluated in this meta-analysis. The H. pylori eradication rate of bismuth quadruple therapy was similar to that of concomitant therapy (intention-to-treat analysis: pooled eradication rates, 85.5% vs 80.7%; odds ratio [OR], 1.42; 95%confidence interval (CI): [0.92–2.18]; P>0.05). The incidence of adverse events in bismuth quadruple therapy was lower than those in concomitant therapy (pooled incidence, 18.3% vs 25.9%; OR, 0.62, 95%CI: [0.41–0.92]; PConclusions: Bismuth quadruple therapy had the same efficacy to concomitant therapy in H. pylori eradication, and bismuth quadruple therapy was possibly better tolerated than concomitant therapy. Therefore, bismuth quadruple therapy and concomitant therapy should be equally recommended as empirical regimens in H. pylori eradication. VL - 8 IS - 4 ER -
Information
Email: